taranabant

Taranabant is a highly selective small molecule inverse agonist of the cannabinoid receptor type 1 (CB1). It was developed by Merck & Co as a potential treatment for obesity due to its anorectic effects. Taranabant acts centrally in the brain, where it occupies CB1 receptors and induces weight loss primarily by reducing food intake and increasing energy expenditure. Clinical trials demonstrated that taranabant could achieve significant weight loss compared to placebo; however, its development was discontinued after Phase III trials due to dose-related adverse effects, particularly gastrointestinal and psychiatric side effects such as increased anxiety, depression, and irritability[1][5][7][8].

Other names

Taranabant